跳至主要内容
临床试验/NCT05449717
NCT05449717已完成不适用

A Prospective Cohort Study on the Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis After Treatment for Primary Visceral Leishmaniasis in South Sudan

Epicentre1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2022年5月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Epicentre
入组人数
52
试验地点
1
主要终点
Incidence of post-kala-azar-dermal leishmaniasis (PKDL)

研究概览

简要总结

This study aims to describe the burden of Post-Kala-Azar Dermal Leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis.

详细描述

This prospective, observational cohort study aims to describe the burden of Post-Kala-Azar Dermal Leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis from a hospital in Lankien, South Sudan.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Primary visceral leishmaniasis patients who had a confirmed (serological and/or parasitological) diagnosis at admission, and who were discharged after successful treatment
  • Availability for follow up visits
  • Provision of informed consent, and in the case of minors 12 to 17 years of age, assent as well

排除标准

  • Unavailability for follow-up visits due to distance, inaccessibility, or refusal to participate
  • Diagnosis of prior primary visceral leishmaniasis done only on clinical basis

结局指标

主要结局

Incidence of post-kala-azar-dermal leishmaniasis (PKDL)

时间窗: 12 months

To determine the incidence of PDKL after initial successful treatment of primary visceral leishmaniasis (VL) over a period of 12 months

Incidence of VL relapse

时间窗: 12 months

To determine the incidence of VL relapse after initial successful treatment of primary VL over a period of 12 months

次要结局

  • Characterize PKDL lesions(12 months)
  • Time of onset of visceral leishmaniasis (VL) relapse or post-kala-azar-dermal leishmaniasis (PKDL)(12 months)
  • Rate and time period to self-healing of PKDL(12 months)
  • Risk factors for the development of VL relapse or PKDL(12 months)

研究者

发起方
Epicentre
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验